{'fraction_non_alphanumeric': 0.04032258064516129, 'fraction_numerical': 0.03064516129032258, 'mean_word_length': 5.187032418952619, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cognitive function changes and associated factors in patients receiving chemotherapy

Abstract Background Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies.In recent years, growing attention is being paid to the potential adverse effects of chemotherapy on brain and cognitive function. Despite the accumulation of knowledge on the cognitive side-effects of chemotherapy, the actual incidence of this impairment is still a subject of research. Estimates of affected patients vary from 17% to 78% across studies. The aim of the study is to evaluate cognitive function changes experienced by cancer patients who receive chemotherapy and associated factors. Methods This is a descriptive study. The data collection phase of the study is ongoing and the results obtained from 47 patients who received chemotherapy have been reported here. The results of the large group will be presented at the congress. Data collection was started on March 2019 and will be continuing until September 2019. This study was conducted in a Research and Training Hospital in Istanbul/Turkey. Data were collected by using the Patient Information form and Functional Assessment of Chronic Illness Therapy- Cognitive Function (FACIT-Cog) and The European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). Mann-Whitney U test, Kruskal-Wallis test, and Spearman Correlation analysis were used to evaluate the data. Results There was statistically significant and positive relationship between FACIT-Cog “perceived cognitive impairments” subscale and EORTC-30 cognitive (r = 0,755; p ≤ 0,001), emotional (r = 0,505; p = 0,001) and social (r = 0,504; p = 0,001) functioning subscales. There was statistically significant and positive relationship between FACIT-Cog “comments from others on cognitive function” and EORTC-30 emotional (r = 0,491; p = 0,001), cognitive (r = 0,539; p ≤ 0,001), and social (r = 0,588; p ≤ 0,001) functioning subscales. FACIT-Cog scores was not significantly differ by patients’ characteristics (p > 0,005). Conclusions Cognitive function should be assessed and considered during the care of cancer patients. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.